Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 5 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
Generation Bio Co. has 6 pending office actions in Biotechnology & Pharmaceuticals. The matters are assigned across 6 distinct examiners and 6 distinct art units, with each listed matter associated with a separate examiner and unit. That distribution suggests that prosecution management will depend on matter-level tracking rather than resolution of a single recurring examination relationship.
CABRAL, ROBERT S is the busiest examiner, with 1 pending matter. The examiner workload is therefore dispersed across the portfolio. Counsel should maintain separate response strategies while using a common technical and claim framework where the applications share subject matter.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (20%) |
| §112 only | 2 (40%) |
| Double-patenting only | 1 (20%) |
| Multi-statute (no §101) | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CABRAL, ROBERT S | 1 | 62.8% | +32.3% |
| VU, JAKE MINH | 1 | 41.0% | +27.0% |
| LAZARO, DOMINIC | 1 | 63.7% | +31.2% |
| POPA, ILEANA | 1 | 21.7% | +15.7% |
| HIRT, ERIN E | 1 | 40.6% | +22.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18578073 | SINGLE CHAIN VARIABLE FRAGMENT (SCFV) MODIFIED LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF | LAZARO, DOMINIC | — |
| 17925404 | NOVEL LIPIDS AND NANOPARTICLE COMPOSITIONS THEREOF | POPA, ILEANA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19063950 | STEALTH LIPID NANOPARTICLE COMPOSITIONS FOR CELL TARGETING | VU, JAKE MINH | 73d overdue |
| 19238030 | POLYGLYCEROL-CONJUGATED LIPIDS AND LIPID NANOPARTICLE COMPOSITIONS COMPRISING THE SAME | CABRAL, ROBERT S | — |
| 18578073 | SINGLE CHAIN VARIABLE FRAGMENT (SCFV) MODIFIED LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF | LAZARO, DOMINIC | — |
| 17925404 | NOVEL LIPIDS AND NANOPARTICLE COMPOSITIONS THEREOF | POPA, ILEANA | — |
| 17642314 | IONIZABLE LIPIDS AND NANOPARTICLE COMPOSITIONS THEREOF | HIRT, ERIN E | — |
| Art Unit | Apps |
|---|---|
| 1614 | 1 |
| 1618 | 1 |
| 1611 | 1 |
| 1633 | 1 |
| 1616 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19238030 | POLYGLYCEROL-CONJUGATED LIPIDS AND LIPID NANOPARTICLE COMPOSITIONS COMPRISING THE SAME | CABRAL, ROBERT S | 1614 | §112 | Final Rejection | — | Pending | Jun 13, 2025 |
| 19063950 | STEALTH LIPID NANOPARTICLE COMPOSITIONS FOR CELL TARGETING | VU, JAKE MINH | 1618 | DP | Final Rejection | 73d overdue | Pending | Feb 26, 2025 |
| 18578073 | SINGLE CHAIN VARIABLE FRAGMENT (SCFV) MODIFIED LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF | LAZARO, DOMINIC | 1611 | §103§112 | Non-Final OA | — | Pending | Jan 10, 2024 |
| 17925404 | NOVEL LIPIDS AND NANOPARTICLE COMPOSITIONS THEREOF | POPA, ILEANA | 1633 | §103 | Final Rejection | — | Pending | Nov 15, 2022 |
| 17642314 | IONIZABLE LIPIDS AND NANOPARTICLE COMPOSITIONS THEREOF | HIRT, ERIN E | 1616 | §112 | Non-Final OA | — | Pending | Mar 11, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGeneration Bio Co. has 5 pending office actions as of October 2026, spread across 5 art units and 5 examiners.
Robert S Cabral has the most, with 1 of Generation Bio Co.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
